Literature DB >> 23243407

"Myxedema madness" associated with newly diagnosed hypothyroidism and obstructive sleep apnea.

J Matthew Neal1, Rodney Joe O Yuhico.   

Abstract

This is the case report of a 32-year-old obese male with a history of agitation, hallucinations, and delirium, recently diagnosed with primary hypothyroidism; he gave a several month history of fatigue with nocturnal snoring and frequent awakening. Polysomnogram revealed severe OSA; initiation of CPAP and levothyroxine resulted in immediate improvement. The lack of a previous psychiatric history and acuteness of presentation was consistent with hypothyroid psychosis complicated by sleep deprivation cause by untreated OSA. Primary hypothyroidism is a common disorder often associated with depression. It is rarely associated with psychosis and was first described as "myxoedematous madness" in 1949. It has not been previously reported to cause psychosis when associated with obstructive sleep apnea. This case illustrates the need for examination of potential multiple organic causes in a patient who presents with psychosis in the critical care setting.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23243407      PMCID: PMC3501670          DOI: 10.5664/jcsm.2274

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  7 in total

1.  Myxedema psychosis with grade II hypothyroidism.

Authors:  Jon A Lehrmann; Shaili Jain
Journal:  Gen Hosp Psychiatry       Date:  2002 Jul-Aug       Impact factor: 3.238

2.  Myxoedematous madness.

Authors:  R ASHER
Journal:  Br Med J       Date:  1949-09-10

Review 3.  Psychiatric effects of thyroid hormone disturbance.

Authors:  R C Hall
Journal:  Psychosomatics       Date:  1983-01       Impact factor: 2.386

4.  Prevalence of thyroid disease in patients with obstructive sleep apnea.

Authors:  Salman A Bahammam; Munir M Sharif; Anwar A Jammah; Ahmed S Bahammam
Journal:  Respir Med       Date:  2011-08-04       Impact factor: 3.415

5.  Psychosis in sleep apnoea.

Authors:  S Lee; H F Chiu; C N Chen
Journal:  Aust N Z J Psychiatry       Date:  1989-12       Impact factor: 5.744

6.  Obstructive sleep apnea in hypothyroidism.

Authors:  K R Rajagopal; P H Abbrecht; S S Derderian; C Pickett; F Hofeldt; C J Tellis; C W Zwillich
Journal:  Ann Intern Med       Date:  1984-10       Impact factor: 25.391

7.  Hypothyroidism Presenting as Psychosis: Myxedema Madness Revisited.

Authors:  Thomas W. Heinrich; Garth Grahm
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-12
  7 in total
  5 in total

1.  Sustained remission of psychotic symptoms secondary to hypothyroidism (myxedema psychosis) after 6 months of treatment primarily with levothyroxine: a case report.

Authors:  Eric C Chan
Journal:  J Med Case Rep       Date:  2022-10-20

Review 2.  Delirium in patients with cancer: assessment, impact, mechanisms and management.

Authors:  Peter G Lawlor; Shirley H Bush
Journal:  Nat Rev Clin Oncol       Date:  2014-09-02       Impact factor: 66.675

Review 3.  The relation between thyroid dysregulation and impaired cognition/behaviour: An integrative review.

Authors:  Manizhe Eslami-Amirabadi; Seyed Ahmad Sajjadi
Journal:  J Neuroendocrinol       Date:  2021-03       Impact factor: 3.627

4.  Comparisons of thyroid hormone, intelligence, attention, and quality of life in children with obstructive sleep apnea hypopnea syndrome before and after endoscopic adenoidectomy.

Authors:  Hui-Wei Feng; Tao Jiang; Hong-Ping Zhang; Zhe Wang; Hai-Ling Zhang; Hui Zhang; Xue-Mei Chen; Xian-Liang Fan; Yu-Dong Tian; Tao Jia
Journal:  Biomed Res Int       Date:  2015-01-15       Impact factor: 3.411

Review 5.  Myxedema Psychosis: Systematic Review and Pooled Analysis.

Authors:  Mouhand F H Mohamed; Mohammed Danjuma; Mohammed Mohammed; Samreen Mohamed; Martin Siepmann; Kristian Barlinn; Salah Suwileh; Lina Abdalla; Dabia Al-Mohanadi; Juan Carlos Silva Godínez; Abdel-Naser Elzouki; Timo Siepmann
Journal:  Neuropsychiatr Dis Treat       Date:  2021-08-18       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.